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Ancora Pharmaceuticals: Overview
•Demonstrated track record in producing commercially 
relevant synthetic carbohydrates across the 
glycobiology spectrum
•Founded on the groundbreaking carbohydrate synthesis 
technology from Prof. Dr. Peter Seeberger (Max Planck)
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•Primary R&D focus: glycoconjugate vaccines for 
prevention of nosocomial and opportunistic infections
•World class team of managers and advisors
©2012 Ancora Pharmaceuticals Inc.
•Business focus: build value through partnered and 
proprietary programs
Management and Advisors
• Richard Hoffman, J.D., M.B.A. CEO;  20+ years in biopharmaceutical corporate and 
business development (Abgenix, Ablexis)
• Stewart Campbell, Ph.D.  Vice President - Research & Development; 18 years in 
biopharmaceutical therapeutic development; 16 years carbohydrate chemistry expertise.
• Obadiah Plante, Ph.D.  Co-founder, Senior Director - Vaccine Discovery; 15 years 
carbohydrate chemistry expertise.
• Professor Peter Seeberger, Ph.D. Director, Scientific Founder; World leader in 
carbohydrate chemistry and glycobiology; Elected Director of the Max Planck Institute
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• Barry Buckland, Ph.D. Director and Scientific Advisor; ex-VP Bioprocess for Merck 
Vaccines; 30+ years vaccine & biologic product development
• Florian Schodel, M.D.  Scientific Advisor; ex-VP Clinical Development for Merck 
Vaccines; 20+ years vaccine research and clinical development
• George M. Siber, M.D. Scientific Advisor; ex-CSO for Wyeth Vaccines; 30+ years 
vaccine research & development
• Bruce Forrest, M.D., M.B.A. Corporate and Scientific Advisor; ex-SVP Vaccine 
Research & Development for Wyeth Vaccines (Pfizer); 20+ years vaccine research and 
clinical development
• Rahul Singhvi, Sc.D., MBA. Director; former President/CEO of Novavax; former 
scientist at Merck Vaccines.
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• Commercially Validated Approach: 
– Why only 3 pathogens addressed so far?
Glycoconjugate Vaccines –
Proven Products, Persistent Barriers
• Pneumococcus 
– Prevnar®
– Synflorix®
• Hib:
– Comvax®
– HibTITER®
– Hiberix®
• Meningococcus
– Menactra®
– Menveo®
4©2012 Ancora Pharmaceuticals Inc.
• Major Barrier: 
– Limited access to defined carbohydrate material
Carbohydrate Production:
State-of-the-Art BioProcessing Can Be Limiting
Biological
material source Isolated material
Purified average
structures
5
Development
(CTM)
Discovery
(POC)
Bioprocesses yield average structures (mixtures) which can
impede every stage:
Commercial
(Mfg)
Bacterial surface
Target antigen Impurity
©2012 Ancora Pharmaceuticals Inc.
Chemical Synthesis Platform Unlocks 
Carbohydrate Space
Building block Assembly Processing 
Ancora synthesis technology platform produces defined structures
6
technology capabilities methodologies
No limitation to structure or material access –
Ancora has completed every target structure to date
Opens entire glycobiology application space
©2012 Ancora Pharmaceuticals Inc.
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Demonstrated Production of Diverse, Complex 
Mammalian Carbohydrate Structures
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Demonstrated Production of Diverse, Complex 
Pathogen Carbohydrate Structures
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Ancora Platform Provides Access to
Virtually Any Complex Carbohydrate Structure
Vaccine discovery
Example:
Leishmania LOS
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Repeating
saccharide units
Inner core
structures
Terminal,
variable structures
Design and optimize for desired biological profile
©2012 Ancora Pharmaceuticals Inc.
Attributes of Synthetic Carbohydrate Antigen 
Approach
Unattainable 
structures
Conjugation 
control
Antigen
“Med Chem”
Vaccine discovery
Optimization
Epitope mapping
Presentation
Loading
New targets
“Core” structures
10
Large scale, 
well-defined
antigens
Vaccine development
Regulatory
Manufacturing
Safety
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Synthetic Antigens Provide 
Excellent Conjugation Control
Purified
Candida β-glucan conjugates Group A Strep PS conjugates
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Retention time
Synthetic
Bromuro et al. Vaccine  28 (2010) 2615
(Novartis Vaccines)
Kabanova et al. Vaccine  29 (2010) 104
(Novartis Vaccines)
Retention time
Ancora Platform Capabilities: Scalable to Support 
Discovery Through Early Clinical Trials
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Cost Competitive
Ancora Vaccine Portfolio:
Focus on Nosocomial Infections
Program
Chemistry Biological Function Preclinical Development Clinical Development
Ag Design Ag Synthesis Immunogenic In vitro In vivo Scale-Up Formulation Safety Phase I Phase II Phase III
NOSOCOMIAL
Staphylococcus Partnered
Pseudomonas
Enterococcus
Candida
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COMMUNITY
Moraxella
BIODEFENSE
Burkholderia
In Progress
©2012 Ancora Pharmaceuticals Inc.
Staphylococcus Vaccine Program:
Antigen Optimization via “Med Chem”
14©2012 Ancora Pharmaceuticals Inc.
• Target Populations and Medical Need:
• Incidence: 
• > 1.7 MM nosocomial infections annually
• CoNS and S. aureus in top five
• At-risk populations:
• Elective Cardiovascular Surgery – 7 MM procedures
• Orthopedic Surgery – > 1 MM procedures
• End-Stage Renal Disease – 600,000 patients
Staphylococcus Vaccine Opportunity
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• High drug resistance (MRSA), high mortality rate (20% of HAI)
• High economic burden:  >$30,000/ICU patient
• Staphylococcus as a Target:
• Gram positive, biofilm producing bacterium
• Usually encapsulated (Types 5, 8, 336 account for most human infections)
• Complex infection life-cycle  multi-valent approach likely required
©2011 Ancora Pharmaceuticals Inc.
Staphylococcal PIA/PNAG: 
Major Biofilm Component and Virulence Factor
ancora
Coagulase
Polysaccharide
Capsule Peptidoglycan
dPNAG
(adhered)
PNAG (secreted) forms
basis of biofilm
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Int. J. Antimicrob. Ag. (2008) 32S:S71
J. Infect. Dis. (2005) 192:2012
• dPNAG provide physical interface between bacterium and biofilm
• Human anti-dPNAG antibody levels correlated with in vitro OPA activity
Precedent for PNAG as a Target Antigen:
Purified PS & Purified DT-Conjugate
Purified PNAG Mixtures
(Pier et al.)
Numerous
Potential 
Conjugation 
DT
DT-Conjugates of purified
PNAG Mixtures (Pier et al.)
Partial deacetylation,
Conjugation
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GlcNAc/GlcNH2
subunit
Pier group Science 284 (1999) 1523
Pier group Infect Immun 73 (2005) 6752
Antigen size, functional group pattern, conjugation UNCONTROLLED
Sites
Immunogenic; active in vitro and in vivo
Deacetylation required for immunoprotection  optimum pattern UNCLEAR
©2012 Ancora Pharmaceuticals Inc.
dPNAG Antigen Chemical Space:
Defining the Problem
100 %
OHO
HO O
O
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Vast chemical space defined  > 1030 permutations in DP x Degree alone 
Length (DP)
Acetylation
Degree
Acetylation
Pattern
1 100
0 %
Irregular
Regular
NHR
OHO
HO
NHR
O
n
R = H, Ac
Requires directed empirical and rational approach
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Synthetic PNAG/dPNAG fragments 
covering two extremes:  
fully N-acetylated, fully N-deacetylated
Precedent for PNAG as a Target Antigen:
Synthetic TT-Conjugates
O
OHO
HO
NHR
O
LINKER
n
R = Uniformly H or Ac
n = 5 or 9
TT
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Showed synthetic dPNAG conjugate 
provides passive immunoprotection
Pier, Nifantiev groups Infect Immun 78 (2010) 764
Acetylation patterns, pattern repeats 
not addressed
Protection after active immunization not 
demonstrated
©2012 Ancora Pharmaceuticals Inc.
dPNAG Chemical Space:
State-of-the Art versus Ancora
100 %
OHO
O
20
Ancora platform:
• Grants access to the ENTIRE dPNAG chemical space
• Enables systematic and rational optimization of antigen structure
Length (DP)
N-Acetylation
Degree
N-Acetylation
Pattern
1 100
0 %
Irregular
Regular Pier synthesis
©2011 Ancora Pharmaceuticals Inc.
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Ancora Staphylococcus Vaccine Program: 
Synthetic Antigens with Defined Patterns
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Ag 7
Ag 8
Ag 9
n
Defined Pattern 3
“Medicinal Chemistry” approach to identifying best Ag
R = Patterned H, Ac
Antigen size, functional group pattern, conjugation are EXACT
Rational antigen library design  head-to-head testing
©2011 Ancora Pharmaceuticals Inc.
Staphylococcus Vaccine Program:
Functional Proof-of-Concept
In vitro opsonophagocytosis assay (OPA):
Complement-mediated killing by human PMN’s
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In vitro: Antisera selectively bind bacteria (WBE)
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In Vivo Proof-of-Concept:
Murine Lethal Challenge Model
• S. aureus Newman inoculum: 
5.6 x 108 (LD50)
• CD1 outbred mice 
(n = 10 per group)
• Schedule: 3 x 10 ug @ 11-day 
intervals, rest 14d, i.v. challenge
n = 10
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• Trend: dPNAG-KLH conjugates showed better protection vs. controls
• PNAG-KLH no better than controls
UntreatedPNAG-
KLH
dPNAG2-
KLH
dPNAG1-
KLH
KLH/
adjuvant
Vaccine groups Control groups
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Staphylococcus Vaccine Program:
Competing Antibodies Phenomenon
• Lee, Pier and coworkers characterized 
neutralizing effect of combined anti-CP and anti-
dPNAG Abs both in vitro (OPA) and in vivo
(bacteremia, skin abscess models)
• Identified the same phenomenon in sera from 
bacteremia patients
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Skurnik et al. J. Clin. Invest.  120 (2010) 3220
• Traced mechanism to direct binding of 
respective variable regions to each other
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Staphylococcus Vaccine Program:
Potential Solution to Competing Antibodies
New dPNAG Antigen Design Criteria
• ≤ 50% N-acetylation degree
• de-N-acetylated residues spaced by two 
intervening residues were disallowed
• ≤ 2 de-N-acetylated residues allowed in positions 
complementary to the CP ManAcA residues in an 
entire sequence (length dependent)
• ≤ 3 consecutive N-acetylated residues allowed
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1 = NHAc 
0 = NH2
Permutations for dp = 10
Binary 
algorithm
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• Minimize overall length 
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Desired output: Improved antigen devoid of anti-CP interference properties
Moraxella Vaccine Program:
Targeting Novel “Core Structures”
26©2012 Ancora Pharmaceuticals Inc.
Moraxella catarrhalis Vaccine Program
Target Antigen Overview: β-chain
Significant unmet medical need
• COPD: Over 2 million infections annually (2nd)
• Otitis media: Over 30% of acute otitis media cases (3rd)
• A leading cause of LRTIs in vulnerable populations  
• Widespread drug resistance
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• Gram negative lipo-oligosaccharide (LOS) class
• Critical for survival and virulence
• A, B, and C serotypes:  95% of human infections
• Validated target in vitro and in vivo
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OH HO
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Kdo
α-chain
Peng et al. FEBS J 274 (2007) 5350
Goal:   Identify antigen structures and substructures cross-
protective across all major MXLA strains
LOS core oligosaccharide
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Moraxella Vaccine Program:
Antigen Design
Chemistry provides unique systematic approach to core structures
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Moraxella Vaccine Program: 
Cross Reactivity ELISA of Rabbit Antisera
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Analogs 4 and 5 show significant, broad cross-reactivity
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Moraxella Vaccine Program:
Serum Bactericidal Assay (SBA) Data
50%
Threshold
40
60
80
100
1:2
1:10
1:50
1:250
%
 
K
i
l
l
i
n
g
Serotype A
ATCC 25238
30Study: AP-PD-0014
SBA titers ≤ 1:250 for parent and cross-reactive Ag’s (n = 4 mean shown)
0
20
KLH Neg Ctrl Analog 3 Analog 4 ST A Analog 5
ELISA cross-reactivity translates into SBA activity
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Pseudomonas Vaccine Program:
Targeting Biofilm & “Hybrid Core” Structures
31©2012 Ancora Pharmaceuticals Inc.
Pseudomonas Vaccine Program
Significant Market Opportunity:
•2nd leading cause of ventilator associated pneumonia
•3rd leading cause of hospital-acquired pneumonia
•CF Patients: Most common lung infection, leading cause of 
morbidity and mortality
•Antibiotic resistance reaching critical level
P. aeruginosa
32
Target Antigen Overview:
• 3 potential targets based on conserved nature, 
virulence role and colonization
• Alginate biofilm (1) expressed in chronic 
mucoid infections
• O-antigens (2) expressed in acute non-mucoid
infections
• LOS core (3) expressed in all infection stages
©2012 Ancora Pharmaceuticals Inc.
Outer Membrane
Biofilm
1
2
3
Trends Mol. Med.  (2008) 14:120
Pseucomonas Vaccine Program:
Automated Synthesis of Alginate Antigen
Design and Chemistry Approach
• Series of β-mannuronic acids of varying length
• Assembled in a day from a one building block 
(1) using Ancora’s automated synthesizer 
• Functional group for subsequent conjugation
• Evaluation in progress 
• Collaboration with Leiden University
33©2011 Ancora Pharmaceuticals Inc.
Walvoort et al. Angew. Chem. Int. Ed. 51 (2012) 4393
Ancora‘s automated carbohydrate synthesizer
Ancora Summary
• Diverse, broadly applicable carbohydrate synthesis platform
• Demonstrated track record of generating relevant synthetic 
carbohydrate antigens (defined, homogeneous)
• Internal focus on glycoconjugate vaccines for the prevention of 
nosocomial and other infections
• Excellent team of experienced managers and advisors
• Business strategy: partner after demonstration of preclinical POC
©2012 Ancora Pharmaceuticals Inc.
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